The b-catenin gene (CTNNB1) has been shown to be genetically mutated in various human malignancies. To determine whether the b-catenin gene is responsible for oncogenesis in thoracic malignancies, we searched for the mutation in 166 lung cancers (90 primary tumors and 76 cell lines), one blastoma and 10 malignant mesotheliomas (two primary tumors and eight cell lines). Among the lung cancers, including 43 small cell lung cancers (SCLCs) and 123 non-small cell lung cancers (NSCLCs), we identi®ed four alterations in exon 3, which is the target region of mutation for stabilizing bcatenin. One primary adenocarcinoma had a somatic mutation from C to G, leading to an amino acid substitution from Ser to Cys at codon 37. Among the cell lines, SCLC NCI-H1092 had a mutation from A to G, leading to an Asp to Gly substitution at codon 6, NSCLC HCC15 had a mutation from C to T, leading to a Ser to Phe substitution at codon 45, and NSCLC NCI-H358 had a mutation from A to G, leading to a Thr to Ala substitution at codon 75. One blastoma also had a somatic mutation from C to G, leading to a Ser to Cys substitution at codon 37. Among the 10 malignant mesotheliomas, we identi®ed a homozygous deletion in the NCI-H28 cell line. Cloning of the rearranged fragment from NCI-H28 indicated that all the exons except exon 1 of the b-catenin gene are deleted and that the deletion junction is 13 kb downstream from exon 1. Furthermore, Northern blot analysis of 26 lung cancer and eight mesothelioma cell line RNAs detected ubiquitous expression of the b-catenin messages except NCI-H28, although Western blot analysis showed that relatively less amounts of protein products were expressed in some of lung cancer cell lines. Our ®ndings suggest that the b-catenin gene is infrequently mutated in lung cancer and that the NCI-H28 homozygous deletion
Introduction
The cytoplasmic b-catenin protein is implicated in a component of a cell ± cell adhesion regulator when coupled with cadherin and is also considered as a member in the wingless/Wnt signal transduction pathway (Eastman and Grosschedl, 1999) . In the absence of a wingless/Wnt signal, b-catenin is eciently degraded by the ubiquitin-proteasome system. The targeting of b-catenin for degradation involves phosphorylation by GSK (glycogen synthase kinase)-3b on serine/threonine residues encoded in exon 3, which requires engagement of b-catenin in a multiprotein complex that involves, in addition to b-catenin and GSK, the tumor suppressor gene product APC and axin. Genetic alterations of the b-catenin or APC genes result in stabilization of bcatenin and a signi®cant increase of this protein within the cell, followed by translocation to the nuclei and serving as a transcriptional factor through binding to the Tcf/Lef family. In colon cancers, it has been demonstrated that tumors with APC mutations showed no mutations in b-catenin, whereas b-catenin mutations were found in nearly 50% of the cancers with wild-type APC (Sparks et al., 1998) . Besides colon cancer, various types of human tumors including liver, endometrium, ovary, prostate, stomach and anaplastic thyroid cancer, the b-catenin gene is activated via point mutation or deletion of exon 3 that codes a regulatory element required for protein degradation (Fukuchi et al., 1998; Garcia-Rostan et al., 1999; Iwao et al., 1998; Miyoshi et al., 1998; Morin et al., 1997; Palacios and Gamallo, 1998; Park et al., 1999; Voeller et al., 1998) . The AXIN1 gene encoding axin has also been found to be inactivated in hepatocellular carcinoma (Satoh et al., 2000) .
So far, only a few studies have been reported for bcatenin gene alterations in lung cancer and none reported for malignant mesothelioma. Ninety-three lung cancers have been studied for the exon 3 mutation of the b-catenin gene (Sunaga et al., 2001) . Missense mutations causing substitutions of Ser/Thr residues critical for the regulation by GSK-3b were detected in one (2%) of the cell lines, A427, and two (4%) of the surgical specimens, with all subtypes being adenocarcinomas. A427 was also shown to be constitutionally activated for Tcf transcriptional activity. Meanwhile, alteration of expression of cadherins and catenins have been detected in lung cancer (Hidaka et al., 1998; Nawrocki et al., 1998; Smythe et al., 1999) and implicated in prognosis of patients with lung cancer (Kase et al., 2000; Retera et al., 1998) .
In the present study, we identi®ed that the b-catenin gene is mutated in a subset of lung cancer and that some of the lung cancer cell lines express lower amounts of b-catenin protein despite substantial expression of its mRNAs. We also demonstrated that a malignant mesothelioma cell line, NCI-H28, has a homozygous deletion of the b-catenin gene and that the breakpoint is 13 kb downstream from CTNNB1 exon 1 is rearranged to a novel region, which we termed rbc (rearranged to b-catenin).
Results

Searching for mutation of the b-catenin gene
Exon 3 of the b-catenin gene encodes the NH 2 -terminal regulatory domain and its mutation or deletion has been identi®ed as inducing stabilization of b-catenin in various human malignancies. To determine whether lung cancer and malignant mesothelioma also harbor such mutations, we analysed 166 lung cancer (90 primary lung cancers and 76 cell lines), one lung blastoma and 10 malignant mesothelioma DNAs (two primary mesotheliomas and eight cell lines). We ampli®ed exon 3 by PCR with a sense primer residing at exon 2 and an antisense primer at exon 4. Ethidium bromide staining of the PCR products separating on 3% agarose gel showed that all the 166 lung cancer and one blastoma DNAs had the expected 923-basepair (bp) PCR products without any abnormal sized fragments, indicating that no interstitial deletions of exon 3 occurred (data not shown). Meanwhile, sequencing analysis revealed that four lung cancers and one blastoma had mutations that cause amino acid substitutions ( Figure 1a and Table 1 ). One primary adenocarcinoma and one blastoma had the same mutation from C to G, leading to an amino acid substitution from Ser to Cys at codon 37. We sequenced the corresponding DNAs extracted from the non-cancerous lung tissues of these patients and con®rmed that the mutations were somatic. Since one of the characteristic phenomena of b-catenin gene activation is a nuclear localization of the product, we performed immunohistochemical analysis of these specimens. The blastoma from Patient 71, but not the adenocarcinoma from patient 68, showed nucleic accumulation of b-catenin (Figure 1b) . For the lung cancer cell lines, NCI-H1092 had a mutation from A to G, leading to an Asp to Gly substitution at codon 6, HCC15 had a mutation from C to T, leading to a Ser to Phe substitution at codon 45, and NCI-H358 had a mutation from A to G, leading to a Thr to Ala substitution at codon 75. In addition, NCI-H889 showed a nucleotide change of T to G at intron 3, 20 bp downstream from the exon 3 donor site.
Among the 10 malignant mesotheliomas, PCR ampli®cation of exon 3 of the b-catenin gene detected no product in NCI-H28, suggesting the existence of homozygous deletion (data not shown). To character- ize the NCI-H28 homozygous deletion region, we designed additional primer sets for other exons of the b-catenin gene and tested the DNA. PCR analysis detected an expected sized product for exon 1 but not the others, indicating that the NCI-H28 homozygous deletion breakpoint site exists between exons 1 and 2. We also performed Southern blot analysis for NCI-H28 ( Figure 2 ). While an exon 1 probe detected a 18-kb rearranged band in BamHI digestion, the 2344 bp cDNA probe synthesized to cover the entire coding region (nt 215 ± 2558) from exon 2 to exon 15 detected no bands, con®rming the homozygous deletion ( Figure  2b ). The NCI-H28 homozygous deletion encouraged us to study the whole gene to reveal whether other lung cancers and malignant mesotheliomas harbor large deletions besides the exon 3 region. We performed Southern blot analysis for 166 lung cancer, one blastoma, and 10 malignant mesothelioma DNA by the 2344 bp cDNA probe, which detected 4-EcoRI digested fragments (8.6, 4.6, 2.7 and 1.7 kb). However, we did not detect any more deletions or rearrangements (data not shown). Since the NCI-H28 homozygous deletion indicated the unexpected inactiv-ation of the b-catenin gene, we also hypothesized that other malignant mesotheliomas might harbor point mutations for inactivation other than large deletion. To con®rm this, we analysed the entire coding sequence of the seven mesothelioma cell lines by single-strand conformation polymorphism (SSCP) analysis using cDNA with 13 overlapping primer sets. However, we did not ®nd any other changes (data not shown).
Expression of b-catenin in lung cancer and malignant mesothelioma
To determine whether the mRNA and protein product of the b-catenin gene is abnormally expressed without genetic changes, we performed Northern and Western blot analyses. Using the selected 35 lung cancers (24 Figure 3a shows a representative result. To determine whether the remaining exon 1 of NCI-H28 creates chimeric messages that would consist of the exon 1 and unknown exons existing in the rearranged fragment, we synthesized a b-catenin exon 1 probe by PCR and performed Northern blot analysis. NCI-H28 did not show any message, suggesting that this cell line did not express any chimeric mRNA (data not shown). Furthermore, we performed Western blot analysis for b-catenin and found that NCI-H28 did not express any protein product (Figure 3b ). Noticeably, compared with relatively high amount of the mRNAs, some of the cell lines such as NCI-H838, H920, and H460 expressed less amounts of the b-catenin product.
Cloning of the breakpoint of a rearrangement fragment to b-catenin exon 1 of the NCI-H28 cell line
To characterize the NCI-H28 homozygous deletion of the b-catenin gene, we constructed a genomic phage library using high-molecular DNA extracted from NCI-H28 and cloned the breakpoint. Using the exon 1 probe, we screened a total of ®ve million clones at the ®rst screening, walked to the 3' side, and then isolated other phage clones, of which three clones (PD32, PD36, and PD72) were further characterized in detail (Figure 4a ). Sequencing analysis and construction of restriction enzyme maps of these clones and Genbank search revealed that the breakpoint is located at 13 kb downstream from exon 1 and 10 kb upstream from exon 2 (Figure 4b ). We termed the rearranged region rbc, which is rearranged to b-catenin. Based on the sequence of the rbc region, we performed an inverted PCR using normal DNA as a template and obtained the 5' upstream sequence from the breakpoint of the rearranged fragment. We con®rmed the aberrant 18 kb BamHI fragment in NCI-H28 was detected by PCR probe synthesized based on the rbc sequence ( Figure 2c ). Furthermore, PCR analysis speci®c for the chimera further con®rmed that the expected sized product (596 bp) was ampli®ed for NCI-H28 but not others ( Figure 4c ). To determine whether the rbc region was originated from chromosome 3, we performed Southern blot analysis of the human ± rodent somatic cell hybrid panel using the rearranged fragment as a probe. The positive band was detected on DNAs containing human chromosome 3, suggesting the homozygous deletion resulted from an interstitial deletion (data not shown). In addition, BLAST search for Genbank using the rbc fragment sequence revealed complete match to several un®nished high-throughput genomic sequence clones including AC069215 and AC073217 that have been isolated from chromosome 3. Finally, there have been other two homozyous deletion regions identi®ed at 3p21.3 in lung cancer cell lines, with representative cell lines to be NCI-H740 and NCI-H226, respectively. To determine whether the rbc region is localized to these region, we performed Southern blot analysis using NCI-H740 and NCI-H226. We detected normal-sized bands for these cell line DNAs, suggesting that the newly identi®ed homozygous deletion of NCI-H28 is not overlapped with the known homozygous deletion regions.
Discussion
The present data shows that four of 166 of lung cancers and one of one lung blastoma had a mutation of the b-catenin gene, suggesting its involvment in tumorigenesis of a subset of lung cancer, and that one malignant mesothelioma cell line, NCI-H28, has a homozygous deletion, which completely inactivates the b-catenin gene.
Point mutations of b-catenin were initially reported to be concentrated at potential phosphorylation sites such as serine residues at codons 33, 37 and 45, and a threonine residue at codon 41 (Morin et al., 1997; Rubinfeld et al., 1997) . Following studies have further demonstrated that mutation sites could be detected at other residues in exon 3 (Garcia-Rostan et al., 1999). In our study, somatic mutations found in the primary lung cancer and blastoma were exactly the same mutation of codon 37, and the HCC15 mutation of a TCT to TTT change (S45F) was identical to other cancers reported previously (Sparks et al., 1998) . Thus these three mutations, all of which were targeted serine residues, were thought to be signi®cant changes for lung cancer development. A recent study by another group also reported that three mutations identi®ed from three lung cancers were changes at serine 37 or threonine 41 (Sunaga et al., 2001) . Meanwhile, the sites of two other mutations (N6G in NCI-H1092 and T75A in NCI-H358) were thought to be located relatively apart from the hot spots of the known mutations that have been reported in other malignancies. Since the NCI-H358 mutation was 
(c) PCR analysis of genomic DNAs using a primer set to cross the NCI-H28 breakpoint. A 596 bp abnormal band is ampli®ed for NCI-H28 (lane 2) but not for normal lung (lane 1), NCI-H290 (lane 3), NCI-H2052 DNAs (lane 4) or water blank (lane 5). M; Molecular marker
Oncogene b-catenin mutation in lung cancer and mesothelioma K Shigemitsu et al targeted a threonine residue, we tested whether this mutation causes a nuclear accumulation of b-catenin product. Immunocytochemical analysis of NCI-H358 revealed that b-catenin was localized at the cytoplasm and plasma membrane in most of the cells, although there were a few cells that were stained preferentially at the nucleus (data not shown). Thus, it is possible that the NCI-H358 mutation may not be signi®cant for activating b-catenin although Western blot analysis detected relatively high expression of the product (Figure 3b) .
A recent immunohistochemical study of 331 lung cancer tissues has shown that b-catenin expression was reduced in 122 (37%), which signi®cantly correlated with a poor prognosis for the patients (Kase et al., 2000) . Another report also suggested that reduced bcatenin expression in surgically treated NSCLC was associated with lymph node metastasis and an unfavorable prognosis of the 101 patients (Retera et al., 1998) . These two studies have suggested that downregulation, but not overexpression, is associated with a poor prognosis in lung cancer, which is usually characteristic for tumor suppressor genes (TSGs) but not for oncogenes. Although studies by us and another group suggest that activating mutations of b-catenin may participate in tumorigenesis of a small subset of lung cancer, downregulation of b-catenin may also be associated with other biological phenotypes of lung cancer. In this study, we noticed that bcatenin protein expression of several NSCLC cell lines was relatively low regardless of substantial expression of its mRNAs (Figure 3) . Thus, it has been speculated that posttranslational modi®cation of b-catenin such as phosphorylation may be accelerated in these cell lines.
Cytogenetic analyses have demonstrated that most malignant mesotheliomas have several recurrent abnormalities including losses or structural rearrangements of 1p, 3p, 4, 6q, 9p, 14 and 22, and gains of chromosomes 5, 7, and 20 (Bell et al., 1997; Flejter et al., 1989; Gibas et al., 1986; Hagemeijer et al., 1990; Popescu et al., 1988; Taguchi et al., 1993; Tiainen et al., 1989) . Within these regions, several TSGs have been suggested to be involved in the pathogenesis of malignant mesothelioma, including the p16
INK4A gene located at 9p and the neuro®bro-matosis type 2 gene located at 22q (Bianchi et al., 1995; Cheng et al., 1994; Sekido et al., 1995) . It has been well documented that malignant mesothelioma, as well as other types of human malignancies including lung cancer, shows frequent loss of heterozygosity (LOH) at chromosome 3p. A previous study has shown that, among 24 malignant mesothelioma cases informative at one or more 3p loci, 15 (62.5%) exhibited LOH with at least one marker of seven DNA markers of 3p (Lu et al., 1994) . The common region of chromosomal loss resides within band 3p21 in the vicinity of the D3F15S2 locus, anked by the loci D3S2 (located at 3p21.1) and THRB (located at 3p24.1-p22), suggesting that 3p21 LOH is a frequent occurrence in malignant mesothelioma and that one or more putative TSGs at this site contribute to the pathogenesis of malignant mesothelioma (Lu et al., 1994) . Thus, our study may suggest that the H28 homozygous deletion at 3p21.3 indicates a possibile TSG in this region. A recent study by Calvo et al. (2000) has also reported the identi®cation of the homozygous deletion of NCI-H28, although genetical studies have not been performed in detail.
In the chromosomal 3p region, it has also been reported the existence of ®ve separate homozygous deletion regions in lung cancer cell lines, with three regions at 3p21.3, where the b-catenin gene is localized (Sekido et al., 1998b) . One region has three SCLC homozygous deleted cell lines, NCI-H740, NCI-H1450, and GLC20 and one breast cancer cell line, HCC1500, indicating the minimum common deleted region to 7120 kb (Sekido et al., 1998a) . Several candidate genes including SEMA3B, SEMA3F, CAC-NA2D2 have been identi®ed at the deletion region (Gao et al., 2000; Roche et al., 1996; Sekido et al., 1996; Xiang et al., 1996) , and the RASSF1 gene has been proposed to be a targetted TSG owing to its frequent inactivation by hypermethylation in many lung cancers (Dammann et al., 2000) . The other two regions around the 3p21.3 are the 3p21.3-22 region including ®ve SCLC cell lines including ACC-LC-5 (Yamakawa et al., 1993) and the another 3p21.3 region harboring the BAP1 gene region that has been deleteted in one NSCLC cell line, NCI-H226 (Jensen et al., 1998) . We studied whether the NCI-H28 homozygous deletion was overlapped with these deletion regions and found the H28 deletion is unique at least from the NCI-H740 and NCI-H226 deletion regions.
Because H28 is a b-catenin null cell line, it may be also useful for studying the wnt signaling cascade. For example, although the involvement of b-catenin in wnt signaling is well documented (Behrens et al., 1996) , plakoglobin (g-catenin), which is highly homologous to b-catenin, has not been documented to play a signaling role (Simcha et al., 1998) . Plakoglobin can also bind to LEF-1 and, when overexpressed in mammalian cells, enhances LEF-1-directed transcription, although a plakoglobin and LEF-1 complex may be very inecient in binding DNA or in forming a ternary complex containing LEF-1 and the LEF-1 binding DNA sequences (Zhurinsky et al., 2000) . It has also been suggested that overexpression of plakoglobin does not directly activate transcription and that plakoglobin induces transcription indirectly by elevating the level of endogenous b-catenin through blocking degradation of b-catenin in the cytoplasm (Zhurinsky et al., 2000) . Thus, NCI-H28 cells can be analysed to address the question whether plakoglobin can directly induce gene expression. We have detected that NCI-H28 cells express plakoglobin and Ncadherin, but not E-cadherin, by Western blot analysis (data not shown) and are currently analysing whether plakoglobin also aects genes transcribed by LEF-1/bcatenin complex.
b-catenin mutation in lung cancer and mesothelioma K Shigemitsu et al Eight malignant mesothelioma cell lines and two surgical specimens of malignant mesothelioma were studied. The eight cell lines included four (NCI-H28, H290, H513 and H2052) from the NCI, two (ACC-MESO-1 and ACC-MESO-4) from Aichi Cancer Center in Nagoya, and two (MSTO-211H and NCI-H2453) that were purchased from the American Type Tissue Culture Collection (ATCC) (Rockville, MD, USA). We con®rmed the same genotype of the b-catenin homozygous deletion between NCI-H28 that we have been maintaining in our lab and the one that we repurchased from ATCC.
Materials and methods
Cell lines and tumor samples
Mutational analysis
For detecting exon 3 mutation of b-catenin, 20 ng of genomic DNAs were ampli®ed by a primer set of C-F, 5'-CCA-GCGTGGACAATGGCTAC-3', and C-R, 5'-TGAGCTC-GAGTCATTGCATAC-3', as described previously . The PCR products were sequenced using an Applied Biosystems model 377 DNA sequencer with the C-R primer.
For Southern blot analysis, 7 mg of genomic DNAs, digested with appropriate restriction endonucleases (New England Biolabs, Beverly, MA, USA), were electrophoresed in 0.7% agarose gels, transferred to Hybond N + membranes (Amersham Pharmacia Biotech, Buchinghamshire, UK), hybridized with 32 P-labeled probes synthesized with random primers, and subjected to autoradiography after washing according to the company protocol. Reprobing of the same membranes was performed after stripping of previous probes. For Northern blot analysis, 10 mg of total RNAs were electophoresed in formaldehyde-1% agarose gel and transferred to Hybond N + membranes. The DNA probes used were b-catenin exon-1 probe (281 bp) synthesized by PCR with a primer set of b-cat-S5, 5'-CTTCTGCGCGACTTA-TAAGAG-3', and b-cat-AS6, 5'-CCTGCTACGAAGTT-TGGCTC-3', a 2344 bp cDNA probe covering from nt 215 to nt 2558 (Genbank accession #X87838) synthesized by RT ± PCR with a primer set of b-cat-S1, 5'-ATGGCTACT-CAAGCTGATTTG-3', and b-cat-AS2, 5'-CAGGTCAG-TATCAAACCAGG-3', and rbc probe synthesized by PCR with a primer set of intx-S27, 5'-CAGTAACATAT-TACCTGCCA-3', and intx-AS28, 5'-CATCTAGATGGC-TTTGCAAG-3'.
For detecting a chimeric PCR product from NCI-H28, two primers were synthesized; intx-S13, 5'-CTCTGTTCCTTA-CATGCTG-3', and intx-AS24, 5'-ACCTTCAGATCTTAT-GAGAC-3'.
SSCP analysis was performed as described previously (Sato et al., 2000) . In brief, we developed 13 primer sets from the bcatenin gene sequence to cover entire coding region. The PCR products were electrophoresed on MDE gels (FMC Bioproducts, Rockland, ME, USA) containing 10% or no glycerol.
Western blot and immunohistochemical analyses
Preparation of total cell lysates and Western blotting were performed as described previously (Sekido et al., 1994) . In brief, subcon¯uently growing cells were rinsed two times with phosphate-buered saline, lyzed in SDS sample buer (62.5 mM Tris pH 6.8, 2% sodium dodecyl sulfate, 2% 2-mercaptoethanol, 10% glycerol) and homogenized. Fifteen mg of total cell lysate protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membranes (Millipore, Bedford, MA, USA). Following blocking with 5% nonfat dry milk, the ®lters were incubated with a 1 : 1000 dilution of the ®rst antibody, washed with phosphate-buered saline, reacted with antimouse IgG linked with horseradish peroxidase, and detected with ECL (Amersham Pharmacia). Antibodies used were anti-b-catenin antibody (C19220, Pharmingen/Transduction laboratories, San Diego, CA, USA) and anti-b-actin antibody (A5441, Sigma, St. Lous, MO, USA).
For immunohistochemistry, sections were deparanized in xylene three times for 5 min each then placed in a graded series of ethanol (100, 95 and 80%). The sections were processed to 0.3% H 2 O 2 in methanol for 20 min and then rinsed in PBS three times for 5 min each. The sections were incubated with 10% swine normal serum for 20 min at room temperature. After blocking, sections were incubated overnight at 48C with the anti-b-catenin antibody at 1 : 500 dilution. The sections were rinsed ®ve times with PBS for 3 min each and sequentially incubated with biotinylated secondary antibodies for 30 min at room temperature, rinsed ®ve times for 3 min each with PBS and streptavidin-biotin-peroxidase for 30 min at room temperature, and then rinsed ®ve times with PBS for 3 min. The peroxidase reaction was visualized by making use of a solution of 3,3'-diaminobenzidine tetrahydrochloridesupplemented 0.2% hydrogen peroxidase in PBS.
Construction of genomic library
High molecular weight DNAs of NCI-H28 were extracted by standard methods (Sambrook et al., 1989) . The partially digested NCI-H28 DNA with Sau3A1 was ligated with Lambda FIXII/XhoI partial ®ll-in vector kit (Stratagene, La Volla, CA, USA), packaged with GigapackIII XL packaging extract (Stratagene), and plated on XL1-Blue MRA(P2). Totally, ®ve million plaques were screened with the b-catenin exon 1 probe. Positive clones were characterized with restriction enzyme mapping, sequencing by T7, T3 and internal primers.
Chromosomal assignment
A human-rodent somatic cell hybrid panel (Oncor, Gaithersburg, MD, USA) was used for chromosomal assignment. Hybridization was performed by the rbc probe.
